MMED (NASDAQ:MMED) Earns Outperform Rating from Analysts at William Blair

Stock analysts at William Blair started coverage on shares of MMED (NASDAQ:MMED) in a report issued on Tuesday. The firm set an “outperform” rating on the stock.

MMED has been the topic of several other research reports. Mizuho started coverage on MMED in a report on Tuesday. They set an “outperform” rating and a $21.00 price target on the stock. Wall Street Zen upgraded shares of MMED to a “hold” rating in a research note on Saturday, March 14th. Wells Fargo & Company started coverage on shares of MMED in a report on Tuesday. They set an “overweight” rating and a $26.00 price target for the company. Morgan Stanley initiated coverage on MMED in a research note on Tuesday. They issued an “overweight” rating and a $19.00 price objective on the stock. Finally, Bank of America began coverage on MMED in a report on Tuesday. They issued a “buy” rating and a $27.00 target price on the stock. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, MMED currently has an average rating of “Moderate Buy” and a consensus target price of $22.33.

MMED Stock Performance

MMED opened at $14.35 on Tuesday. MMED has a 52-week low of $14.10 and a 52-week high of $20.48.

MMED Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.